Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04605549 · ClinicalTrials.gov registry record · Phase 2
A Study of CIN-107 in Adults With Primary Aldosteronism
A Phase 2 study of Primary Aldosteronism and Hyperaldosteronism, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 10
- Study locations
NCT04605549 is a Phase 2 study of Primary Aldosteronism and Hyperaldosteronism that has completed, run by AstraZeneca. The registered enrollment target is 15 participants, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT04605549, a Phase 2 study of Primary Aldosteronism and Hyperaldosteronism, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.
Conditions Studied
Interventions
- DRUG CIN-107 2 mg dosing
- DRUG CIN-107 4 mg dosing
- DRUG CIN-107 8 mg dosing
Study Locations (10)
California
- Research Site - Greenbrae
- Research Site - San Francisco
- Research Site - West Hollywood
Ohio
- Research Site - Cincinnati
- Research Site - Columbus
Illinois
- Research Site - Chicago
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Ann Arbor
Minnesota
- Research Site - Rochester
Texas
- Research Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2024-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04605549
The ClinicalTrials.gov registry entry for NCT04605549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Aldosteronism appearing as the primary indexed condition, and to 3 interventions - of which CIN-107 2 mg dosing is the first listed.
NCT04605549 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Ohio, Illinois.
Frequently Asked Questions
What is clinical trial NCT04605549 about?
NCT04605549 is a clinical study titled "A Study of CIN-107 in Adults With Primary Aldosteronism". This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.
What is the current status of trial NCT04605549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-03-08. Estimated completion is 2024-10-28.
What conditions does trial NCT04605549 study?
This clinical trial studies the following conditions: Primary Aldosteronism, Hyperaldosteronism.
What interventions are being tested in trial NCT04605549?
The interventions under investigation include: CIN-107 2 mg dosing (DRUG), CIN-107 4 mg dosing (DRUG), CIN-107 8 mg dosing (DRUG).
Who is sponsoring clinical trial NCT04605549?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04605549 being conducted?
This trial has 10 study locations across California, Illinois, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Aldosteronism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Calcium Channel Blockade in Primary Aldosteronism
COMPLETED · Phase 2
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.